A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Trial Details

NCT ID

NCT07294508

Phase

PHASE2 / PHASE3

Sponsor

Shanghai Henlius Biotech

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• HLX87 + HLX22
• HLX87 + Pertuzumab
• T-Dxd + Pertuzumab
• THP

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• 1\. Have a full understanding of the study content, and sign the informed consent form (ICF); 2. Aged ≥ 18 years at the time of signing the ICF, ma…
• Advanced or metastatic breast cancer.
• HER2-positive as determined by the central laboratory, defined as IHC 3+, or IHC 2+ and ISH+.
• Positive or negative for hormone receptor HR (including estrogen receptor \[ER\] and progesterone receptor \[PgR\]) as determined by the central la…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.